Morgan Stanley has trimmed SINOPHARM's (01099) profit projections for 2025-2030 by 1%-6%, citing reduced sales forecasts within its medical apparatus and pharmaceutical distribution divisions. Consequently, the investment bank adjusted its price target downward from HK$23 to HK$22.5 while maintaining an "Overweight" rating on the stock.

The revised outlook reflects anticipated headwinds in two core business segments, though analysts continue to endorse strategic positioning for long-term growth potential. This recalibration aligns with evolving market dynamics in China's healthcare distribution landscape, where SINOPHARM maintains significant market presence.